Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 26 May

Jessica Amir
May 26, 2020

Morning Bell 25 May

Jessica Amir
May 25, 2020

Weekly Wrap 22 May

Jessica Amir
May 22, 2020

Morning Bell 22 May

Jessica Amir
May 22, 2020

Morning Bell 21 May

Jessica Amir
May 21, 2020

Morning Bell 20 May

Jessica Amir
May 20, 2020

Morning Bell 19 May

Jessica Amir
May 19, 2020

Morning Bell 18 May

Jessica Amir
May 18, 2020

Weekly Wrap 15 May

Jessica Amir
May 15, 2020

Morning Bell 15 May

Jessica Amir
May 15, 2020

Morning Bell 14 May

Jessica Amir
May 14, 2020